T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
- Conditions
- Testicular Germ Cell TumorBreast CancerChronic Myeloproliferative DisordersLeukemiaLymphomaNeuroblastomaOvarian CancerMultiple Myeloma and Plasma Cell NeoplasmGestational Trophoblastic TumorMyelodysplastic Syndromes
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2019-11-15
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 150
- Registration Number
- NCT00651716
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Paclitaxel and Radiation Therapy in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Drug: Post-operative adjuvant therapyDrug: neoadjuvant therapyProcedure: therapeutic surgical procedureRadiation: Radiation therapy with concurrent PaclitaxelDrug: Hormonal Therapy
- First Posted Date
- 2008-03-31
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 38
- Registration Number
- NCT00647218
- Locations
- 🇺🇸
Williamson Medical Center, Frankling, Tennessee, United States
🇺🇸Jackson-Madison Hospital, Jackson, Tennessee, United States
🇺🇸Boston Baskin Cancer Center, Memphis, Tennessee, United States
Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
- Conditions
- Head and Neck Cancer
- Interventions
- First Posted Date
- 2008-03-20
- Last Posted Date
- 2012-09-14
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 41
- Registration Number
- NCT00639769
- Locations
- 🇺🇸
Central Georgia Hematology Oncology Associates, P.C., Macon, Georgia, United States
🇺🇸Erlanger Health System, Chattanooga, Tennessee, United States
🇺🇸Jackson-Madison County Hospital, Jackson, Tennessee, United States
Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery
- Conditions
- Breast Cancer
- Interventions
- Genetic: TUNEL assayGenetic: protein expression analysisOther: immunohistochemistry staining methodOther: laboratory biomarker analysisOther: liquid chromatographyOther: mass spectrometryOther: matrix-assisted laser desorption ionization mass spectrometryProcedure: therapeutic conventional surgery
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2012-09-05
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT00633750
- Locations
- 🇺🇸
University of Alabama, Birmingham, Birmingham, Alabama, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.
- Conditions
- Breast Cancer
- Interventions
- Genetic: fluorescence in situ hybridizationOther: immunohistochemistry staining methodOther: laboratory biomarker analysis
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2012-08-09
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT00611715
- Locations
- 🇺🇸
Central Georgia Hematology/Oncology Associates, P.C., Macon, Georgia, United States
🇺🇸Jennie Stuart Medical Center, Hopkinsville, Kentucky, United States
🇺🇸Purchase Cancer Group, Paducah, Kentucky, United States
Pain Control in Hospice Patients With Cancer-Related Pain
- Conditions
- Solid TumorPain
- First Posted Date
- 2008-02-07
- Last Posted Date
- 2012-10-24
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT00609297
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil
- Conditions
- Graft Versus Host DiseaseLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic Syndromes
- Interventions
- Biological: anti-thymocyte globulinRadiation: total-body irradiation
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT00608517
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States
🇺🇸Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States
🇺🇸Veterans Affairs Medical Center - Nashville, Nashville, Tennessee, United States
Celecoxib in Treating Patients With Early-Stage Rectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- Genetic: gene expression analysisGenetic: protein expression analysisOther: immunohistochemistry staining methodOther: laboratory biomarker analysisOther: mass spectrometryProcedure: biopsyProcedure: neoadjuvant therapyProcedure: therapeutic conventional surgery
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2013-03-05
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT00608595
- Locations
- 🇺🇸
Veterans Administration, Nashville, Tennessee, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
A Multi-Center Phase 2 Study of VEGF Trap as a Single Agent in Acute Myeloid Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2013-04-02
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Registration Number
- NCT00601991
Studying Common Genetic Mutations Related to Mucositis in Patients With Multiple Myeloma Receiving High-Dose Melphalan
- Conditions
- MucositisMultiple Myeloma and Plasma Cell Neoplasm
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2013-03-14
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 95
- Registration Number
- NCT00602147
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States
🇺🇸Veterans Affairs Medical Center - Nashville, Nashville, Tennessee, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States